29th Annual meeting of the Society for Immunotherapy of Cancer (SITC)

Journal for ImmunoTherapy of Cancer

Daniel E Speiser²  Walter J Urba⁵  Kim Margolin⁶  Emanuela Romano⁴  Gregory Verdeil²  Holbrook Kohrt³  Susan Knox⁶  Sylvia Lee⁷  Arthur A Hurwitz¹ 

[1]National Cancer Institute, Frederick, Maryland, USA

[2]Ludwig Center for Cancer Research, Lausanne, Switzerland

[3]Stanford Cancer Institute, Stanford, California, USA

[4]Service of Medical Oncology, University of Lausanne, Lausanne, Switzerland

[5]Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon, USA

[6]Stanford University, Stanford, California, USA

[7]Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

关键词: Immune suppression;    Tumor immunity;    Checkpoint inhibitors;    Immune escape;    Adoptive immunotherapy;    Innate immunity;    Adaptive immunity;    Cancer;    Immunotherapy;   

Others  :  1205873
DOI  :  10.1186/s40425-015-0062-4

 received in 2015-03-05, accepted in 2015-04-17,  发布年份 2015

【 摘 要 】

The 29^th annual meeting of the Society for Immunotherapy of Cancer (SITC) was held November 7-9, 2014 in National Harbor, MD and was organized by Dr. Arthur A. Hurwitz (National Cancer Institute), Dr. Kim A. Margolin (Stanford University), Dr. Daniel E. Speiser (Ludwig Center for Cancer Research, University of Lausanne) and Dr. Walter J. Urba (Earle A. Chiles Research Institute, Providence Cancer Center). This meeting included over 1,600 registered participants from 28 separate countries, making it the largest SITC meeting held to date. It highlighted significant worldwide progress in the development and application of cancer immunology to the practice of clinical oncology, including advances in diagnosis, prognosis and therapy, utilizing several immunological pathways and mechanisms for a variety of oncologic conditions. Presentations and posters demonstrated that many concepts that had been pursued preclinically in the past are now being translated into clinical practice, with clear benefits for patients.

【 授权许可】

   
2015 Hurwitz et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL et al.. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998; 352(9123):179-84.
• [2]Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E et al.. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 2009; 135(10):1429-35.
• [3]Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev. 2008; 222:357-68.
• [4]Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA et al.. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012; 10:1. BioMed Central Full Text